Abstract:The aim of this study was to discover potent angiotensin-converting enzyme (ACE) inhibitory (ACEI) peptides from Pinctada fucata (P. fucata) for treating hypertension and to characterize them using in silico analysis. The P. fucata proteins were hydrolyzed by Alcalase®, a serine endopeptidase with broad selectivity, at various times (0, 2, 4, 6, 8, 10 h). The degree of hydrolysis (DH) and ACEI activity of the different hydrolysates were measured. Considering the molecular weight and ACEI activity, the 10 h hydrolysate was purified by a series of traditional separation methods, including ultrafiltration, gel G-25 chromatography, and reversed-phase high-performance liquid chromatography (RP-HPLC), with ACEI activity as a guide. The results showed two fractions, C17 and C18, eluted by means of semi-preparative RP-HPLC, and showed the highest ACEI activities of 80.33 ± 2.70% and 81.66 ± 0.29%, respectively, at 1 mg mL-1. The two fractions were then identified using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) and their MS/MS spectra data were subjected to de novo sequencing. Subsequently, the potential ACEI peptides were screened by in silico methods, namely, to analyze the average local confidence (ALC) value obtained from the sequencing software and the P-value from the Pepsite 2. In total, 13 potential ACEI peptide sequences were obtained and identified from the two fractions by LC-ESI-MS/MS, and two novel tetrapeptides, FRVW (607.3314 Da) and LPYY (555.2881 Da), were screened for synthesis according to the in silico analysis. The in vitro ACEI tests indicated that FRVW and LPYY had IC50 values of 18.34 and 116.26 μM, respectively. The Lineweaver-Burk plot showed that FRVW was a noncompetitive inhibitor, and LPYY was shown to be a mixed-mode type inhibitor. A stability study against ACE indicated that both peptides were hydrolyzed by ACE to some extent, the higher ACEI activity following incubation with ACE indicating that they should be classified as pro-drug substrates. Molecular docking results showed that hydrophobic amino acids (HAAs) within peptides formed vital interactions including hydrogen bonds, electrostatic forces, van der Waals forces and Pi-Pi interactions with ACE residues, which stabilized the enzyme-peptide complex. Furthermore, the docking results accorded with the inhibition kinetic mode. Our study demonstrated that FRVW and LPYY isolated from P. fucata have potential applications as antihypertensive agents.

Identification of a Novel ACE-inhibitory Peptide from Casein and Evaluation of the Inhibitory Mechanisms.

Analysis And Evaluation Of The Inhibitory Mechanism Of A Novel Angiotensin-I-Converting Enzyme Inhibitory Peptide Derived From Casein Hydrolysate

Angiotensin-I-converting Enzyme Inhibitory Peptides: Chemical Feature Based Pharmacophore Generation

Identification of a Novel ACE-inhibitory Peptide from Sheep Casein and Evaluation of the Molecular Binding Mechanism

Novel Angiotensin I-converting Enzyme Inhibitory Peptides from Protease Hydrolysates of Qula Casein: Quantitative Structure-Activity Relationship Modeling and Molecular Docking Study

Production, Analysis and in Vivo Evaluation of Novel Angiotensin-I-converting Enzyme Inhibitory Peptides from Bovine Casein

Identification and Analysis of Transepithelial Transport Properties of Casein Peptides with Anticoagulant and ACE Inhibitory Activities

Quantitative Structure-Activity Relationship Modeling Coupled with Molecular Docking Analysis in Screening of Angiotensin I-Converting Enzyme Inhibitory Peptides from Qula Casein Hydrolysates Obtained by Two-Enzyme Combination Hydrolysis.

Identification Of An Ace-Inhibitory Peptide From Walnut Protein And Its Evaluation Of The Inhibitory Mechanism

Identification of Bioactive Peptides from a Laminaria digitata Protein Hydrolysate Using In Silico and In Vitro Methods to Identify Angiotensin-1-Converting Enzyme (ACE-1) Inhibitory Peptides

In Silico Identification and Experimental Validation of Two Types of Angiotensin-Converting Enzyme (ACE) and Xanthine Oxidase (XO) Milk Inhibitory Peptides

Identification and characterization of an angiotensin-converting enzyme inhibitory peptide derived from bovine casein

In Vitro and in Silico Analysis of Dual-Function Peptides Derived from Casein Hydrolysate

<i>In vitro-in silico</i> screening strategy and mechanism of angiotensin I-converting enzyme inhibitory peptides from -lactalbumin

Identification and Molecular Mechanism of Angiotensin-Converting Enzyme Inhibitory Peptides from Larimichthys Crocea Titin

Novel ACE Inhibitory Peptides Derived from Whey Protein Hydrolysates: Identification and Molecular Docking Analysis

Isolation and Identification of an Angiotensin-I Converting Enzyme Inhibitory Peptide from Yeast (saccharomyces Cerevisiae)

Identification of Novel Nonapeptides from Sipunculus nudus L. and Comparing Its ACEI Activities Mechanism by Molecular Docking

Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in Vitro Evaluation.

Two novel potent ACEI peptides isolated from Pinctada fucata meat hydrolysates using in silico analysis: identification, screening and inhibitory mechanisms

Angiotensin-I-converting Enzyme Inhibitory Peptides from Tryptic Hydrolysates of Sodium Caseinate